Table 2 CRF results by Cancer type
From: Cancer-related fatigue and activities of daily living: lessons learned from the COVID-19 pandemic
Primary tumor location | Metastatic disease, n (%) | FACIT-F | VAS of CRF | ||||
|---|---|---|---|---|---|---|---|
n (%) | Yes | No | Mean ± SD | CI (95%) | Range | Mean (range) | |
Lung | 19 (31,7) | 11 (18,3) | 8 (13,3) | 33,37 ± 9,71 | 28,69–38,05 | 17–52 | 5,32 (0–9) |
Breast | 16 (26,7) | 2 (3,3) | 14 (23,3) | 32,88 ± 10,99 | 27,02–38,73 | 11–49 | 5,88 (1–8) |
Colorectal | 10 (16,7) | 4 (6,7) | 6 (10) | 37,60 ± 9,26 | 30,97–44,23 | 20–51 | 4,20 (0–9) |
Head and neck | 4 (6,7) | 1 (1,7) | 3 (5) | 38,50 ± 5,91 | 29,09–47,91 | 33–45 | 5,00 (1–7) |
Pancreas | 3 (5,0) | 3 (5) | 0 | 18,00 ± 3,60 | 9,04–26,96 | 14–21 | 7,67 (6–9) |
Kidney | 2 (3,3) | 2 (3,3) | 0 | 27,50 ± 7,77 | -42,38–97,38 | 22–33 | 7,00 (6–8) |
Hematological | 1 (1,7) | 0 | 1 (1,7) | 35,00 -- | -- | 35 | 6,00 |
Bladder | 1 (1,7) | 0 | 1 (1,7) | 31,00 -- | -- | 31 | 8,00 |
Prostate | 1 (1,7) | 1 (1,7) | 0 | 47,00 -- | -- | 47 | 2,00 |
Unknown | 3 (5,0) | 2 (3.3) | 1 (1,7) | 32,67 ± 12,22 | 2,31–63,02 | 22–46 | 5,00 (0–8) |
All | 60 (100) | 26 (43,3) | 34 (65,7) | 33,50 ± 10,11 | 30,68–36,03 | 11–52 | 5,42 (0–9) |